Acadia Pharmaceuticals reported $587.81M in Assets for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Assets Change
Acadia Pharmaceuticals ACAD:US USD 587.81M 14.68M
Alnylam Pharmaceuticals ALNY:US USD 3.55B 11.1M
Aptinyx Inc APTX:US USD 76.2M 16.1M
Biogen BIIB:US USD 24.55B 300.1M
Biomarin Pharmaceutical BMRN:US USD 6.38B 111.03M
Cara Therapeutics CARA:US USD 182.24M 31.27M
Corcept Therapeutics CORT:US USD 583.43M 50.18M
Cytokinetics CYTK:US USD 1.01B 61.19M
Eisai 4523:JP JPY 1.25T 10.21B
Intercept Pharmaceuticals ICPT:US USD 553.71M 5.69M
Intra Cellular Therapies ITCI:US USD 754.78M 27.22M
Marinus Pharmaceuticals MRNS:US USD 259.52M 74.68M
Moderna Inc MRNA:US USD 25.86B 198M
Neurocrine Biosciences NBIX:US USD 2.37B 225.3M
Prothena PRTA:US USD 758.04M 203.6M
Ptc Therapeutics PTCT:US USD 1.71B 129.22M
Sarepta Therapeutics SRPT:US USD 3.13B 27.78M
Seattle Genetics SGEN:US USD 3.67B 55.45M
Ultragenyx Pharmaceutical RARE:US USD 1.55B 73.03M
Vanda Pharmaceuticals VNDA:US USD 634.25M 12.46M
Vertex Pharmaceuticals VRTX:US USD 18.15B 1.44B
YTE INCY:US USD 5.84B 330.77M